Niagen Bioscience (NAGE) Price & Analysis

Compare

554 Followers

NAGE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.63 - $14.69

Previous CloseN/A

VolumeN/A

Average Volume (3M)1.13M

Market Cap

$721.53M

Enterprise Value$0.00

Total Cash (Recent Filing)$44.51M

Total Debt (Recent Filing)$2.65M

Price to Earnings (P/E)54.4

Beta1.04

Next Earnings

Oct 29, 2025

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.06

Shares Outstanding78,769,660

10 Day Avg. Volume1,102,031

30 Day Avg. Volume1,132,102

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$15.30

Price Target Upside58.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Study ResultsNiagen Bioscience announced positive clinical study results that were recently published in the peer-reviewed journal Aging Cell.

Revenue GrowthRevenue outperforms expectations, with Niagen Bioscience reporting $30.5M in top-line revenue, exceeding forecasted figures.

Strategic ExpansionNiagen IV broadens U.S. clinic footprint, poised for further rapid market uptake.

Bears Say

Clinical TrialsKey clinical study in Parkinson's disease remains slated to potentially yield top-line results in 1H25, which could significantly impact the company's prospects.

Market ValuationThere is still little consideration in valuing NAGE's opportunity in rare and orphaned diseases, which is seen as a major positive for NAGE.

Niagen Bioscience News

Niagen Bioscience reports Q2 EPS 4c, consensus 1c

Reports Q2 revenue $31.1M, consensus $28.31M. “We delivered an excellent second quarter, with $31.1 million in net sales,...

2d ago

NAGE

Niagen Bioscience’s Robust Growth and Strategic Initiatives Drive Buy Rating

Canaccord Genuity analyst Susan Anderson has maintained their bullish stance on NAGE stock, giving a Buy rating today....

23h ago

NAGE

Niagen Bioscience Reports Strong Q2 Growth and Outlook

ChromaDex Corporation ( ($NAGE) ) has released its Q2 earnings. Here is a breakdown of the information ChromaDex...

1d ago

NAGE

Niagen Bioscience Reports Strong Q2 Sales Growth

Niagen Bioscience ( ($NAGE) ) has provided an update. On August 6, 2025, Niagen Bioscience reported a 37%...

2d ago

NAGE

Niagen Bioscience: Promising Clinical Results and Strategic IP Acquisitions Drive Buy Rating

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on NAGE stock, giving a Buy rating on...

2d ago

NAGE

Niagen Bioscience Subsidiary Signs Supply Agreement

Niagen Bioscience ( ($NAGE) ) just unveiled an announcement. On July 25, 2025, ChromaDex, Inc., a subsidiary of...

10d ago

NAGE

Niagen Bioscience licenses potential Parkinson’s therapy

Niagen Bioscience (NAGE) announced it has entered into a worldwide exclusive commercial license agreement with Haukeland University Hospital...

1M ago

NAGE

Niagen Bioscience Approves Equity Plan Amendment

Niagen Bioscience ( ($NAGE) ) has issued an update. At the Annual Meeting of Stockholders on June 24,...

1M ago

NAGE

Niagen Bioscience price target raised to $16 from $13 at Canaccord

Canaccord raised the firm’s price target on Niagen Bioscience (NAGE) to $16 from $13 and keeps a Buy...

2M ago

NAGE

Niagen Bioscience presents results in journal Aging Cell

Niagen Bioscience (NAGE) shared results from a clinical study published in the peer-reviewed journal Aging Cell. This is...

2M ago

NAGE

Niagen Bioscience price target raised to $23 from $10 at Roth Capital

Roth Capital raised the firm’s price target on Niagen Bioscience (NAGE) to $23 from $10 and keeps a...

2M ago

NAGE

Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’

Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target...

2M ago

NAGE

Niagen Bioscience initiated with a Buy at Canaccord

Canaccord analyst Susan Anderson initiated coverage of Niagen Bioscience (NAGE) with a Buy rating and $13 price target...

2M ago

NAGE

Niagen Biosciences Reports Strong Q1 2025 Growth

ChromaDex Corporation (($NAGE)) has held its Q1 earnings call. Read on for the main highlights of the call....

3M ago

NAGE

NAGE FAQ

What was Niagen Bioscience, Inc.’s price range in the past 12 months?

Niagen Bioscience, Inc. lowest stock price was $2.63 and its highest was $14.69 in the past 12 months.

What is Niagen Bioscience, Inc.’s market cap?

Niagen Bioscience, Inc.’s market cap is $721.53M.

When is Niagen Bioscience, Inc.’s upcoming earnings report date?

Niagen Bioscience, Inc.’s upcoming earnings report date is Oct 29, 2025 which is in 82 days.

How were Niagen Bioscience, Inc.’s earnings last quarter?

Niagen Bioscience, Inc. released its earnings results on Aug 06, 2025. The company reported $0.057 earnings per share for the quarter, beating the consensus estimate of $0.009 by $0.048.

Is Niagen Bioscience, Inc. overvalued?

According to Wall Street analysts Niagen Bioscience, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Niagen Bioscience, Inc. pay dividends?

Niagen Bioscience, Inc. does not currently pay dividends.

What is Niagen Bioscience, Inc.’s EPS estimate?

Niagen Bioscience, Inc.’s EPS estimate is 0.02.

How many shares outstanding does Niagen Bioscience, Inc. have?

Niagen Bioscience, Inc. has 78,769,660 shares outstanding.

What happened to Niagen Bioscience, Inc.’s price movement after its last earnings report?

Niagen Bioscience, Inc. reported an EPS of $0.057 in its last earnings report, beating expectations of $0.009. Following the earnings report the stock price went up 9.349%.

Which hedge fund is a major shareholder of Niagen Bioscience, Inc.?

Currently, no hedge funds are holding shares in NAGE

Niagen Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

33.47%

Trailing 12-Months

Asset Growth

50.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Niagen Bioscience, Inc.

Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.

Niagen Bioscience (NAGE) Earnings & Revenues

Historic Earnings Reports

NAGE Company Deck

NAGE Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Niagen Biosciences had a strong start to 2025 with significant revenue growth and net income achievement. The company saw impressive growth in e-commerce and ingredients, expanded its Niagen Plus availability, and improved gross margins. However, challenges persist with regulatory issues around NMN and misconceptions about NAD supplements. Additionally, there could be delays in obtaining study results for Parkinson's treatment. Overall, the positive achievements outweigh the challenges.View all NAGE earnings summaries

NAGE Stock 12 Month Forecast

Average Price Target

$15.30

▲(58.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","24":"$24","6.75":"$6.75","12.5":"$12.5","18.25":"$18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.75,12.5,18.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,13.593846153846155,14.377692307692309,15.161538461538463,15.945384615384615,16.72923076923077,17.513076923076923,18.29692307692308,19.08076923076923,19.864615384615384,20.64846153846154,21.432307692307695,22.216153846153844,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,13.001538461538463,13.193076923076923,13.384615384615385,13.576153846153847,13.767692307692307,13.95923076923077,14.150769230769232,14.342307692307692,14.533846153846154,14.725384615384616,14.916923076923077,15.108461538461539,{"y":15.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.81,12.670769230769231,12.531538461538462,12.392307692307693,12.253076923076923,12.113846153846154,11.974615384615385,11.835384615384616,11.696153846153846,11.556923076923077,11.417692307692308,11.278461538461539,11.13923076923077,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.66,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >